+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Blood level of CD45+ platelets and development of restenosis after drug-eluting stent implantation in patients with stable coronary artery disease



Blood level of CD45+ platelets and development of restenosis after drug-eluting stent implantation in patients with stable coronary artery disease



Wiener Klinische Wochenschrift 128(23-24): 898-905



The aim of this study was to assess CD45-positive platelets (CD45+ platelets) involvement in restenosis development after drug-eluting stent (DES) implantation in patients with stable coronary artery disease (CAD). The study comprised 126 male and female patients with stable angina pectoris, who underwent elective coronary stenting with DES and follow-up angiography within 6-12 months. The patients were assigned to the group with restenosis (n = 53) or group without restenosis (n = 73) according to the follow-up angiograms. In both groups we compared the level in blood of CD45+ platelets, the clinical, laboratory and angiographic variables, which may affect the development of restenosis. We have also constructed a logit regression model for prognosis of restenosis occurrence after DES implantation. The blood count of CD45+ platelets was higher in patients with restenosis than in patients without: 0.82 % (0.58; 1.12) vs. 0.34 % (0.20; 0.68), p < 0.001, data are expressed as median (lower quartile; upper quartile). By binary comparisons of more than 35 different clinical, laboratory and angiographic variables we identified 8 significant risk factors for the development of stent restenosis after DES. In order to define the risk of the development of restenosis, we have built a logit regression model. The resulting logit regression equation included the level of CD45+ platelets, the neutrophil to lymphocyte ratio (NLR), small diameter arteries stenting and the number of simultaneously implanted stents in one patient. Receiver operating characteristic (ROC) curve analysis has demonstrated the high prognostic value of the resulting logit regression equation with an area under the curve (AUC) of 0.91 % (p < 0.001). The acquired data indicate the presence of a close relationship between circulating CD45+ platelets and restenosis development after DES implantation in patients with stable CAD.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057314187

Download citation: RISBibTeXText

PMID: 27637207

DOI: 10.1007/s00508-016-1074-x


Related references

Relationship between the Level of Circulating CD45 + Platelets and Development of Restenosis after Implantation of Drug-Eluting Stents to Patients with Coronary Heart Disease. Bulletin of Experimental Biology and Medicine 162(4): 524-527, 2017

Novel Biomarkers for Coronary Restenosis Occurrence After Drug-Eluting Stent Implantation in Patients With Diabetes Having Stable Coronary Artery Disease. Clinical and Applied Thrombosis/Hemostasis 24(8): 1308-1314, 2018

Assessment of novel biomarkers for restenosis occurrence after drug-eluting stent implantation in patients with stable coronary artery disease and type 2 diabetes mellitus. Atherosclerosis 263: E121-E122, 2018

Assessment of novel biomarkers for restenosis occurrence after drug-eluting stent implantation in patients with stable coronary artery disease and type 2 diabetes mellitus. Atherosclerosis 263: E121-E122, 2017

Cost-effectiveness of paclitaxel-coated balloon angioplasty and paclitaxel-eluting stent implantation for treatment of coronary in-stent restenosis in patients with stable coronary artery disease. Clinical Research in Cardiology 101(7): 573-584, 2012

Implantation of a drug-eluting stent with a different drug (switch strategy) in patients with drug-eluting stent restenosis. Results from a prospective multicenter study (RIBS III [Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent]). Jacc. Cardiovascular Interventions 5(7): 728-737, 2012

Implantation of a Drug-Eluting Stent With a Different Drug Switch Strategy in Patients With Drug-Eluting Stent Restenosis Results From a Prospective Multicenter Study RIBS III Restenosis Intra-Stent Balloon Angioplasty Versus Drug-Eluting Stent. 2012

Soluble CD40 ligand release in patients with stable coronary artery disease during elective stent implantation: effect of drug-eluting stent over bare metal stent. Turk Kardiyoloji Dernegi Arsivi 41(8): 675-682, 2013

IVUS-guided management of late stent malaposition with peri-stent restenosis with coronary artery aneurysm following drug-eluting stent implantation (paxlitaxel-eluting stent). Journal of Invasive Cardiology 21(5): E87-E90, 2009

Risk factors of cardiac troponin T elevation in patients with stable coronary artery disease after elective coronary drug-eluting stent implantation. Clinical Cardiology 34(12): 768-773, 2011

Prognostic value of plasma pentraxin-3 levels in patients with stable coronary artery disease after drug-eluting stent implantation. Mediators of Inflammation 2014: 963096, 2014

Incidence, predictors, treatment, and long-term prognosis of patients with restenosis after drug-eluting stent implantation for unprotected left main coronary artery disease. Journal of the American College of Cardiology 57(12): 1349-1358, 2011

Antiplatelet Efficacy of Fixed-Dose Aspirin-Clopidogrel Combination in Patients with Stable Coronary Artery Disease Treated with Drug-Eluting Stent Implantation. Clinical Drug Investigation 35(12): 833-842, 2015

Prognostic Value of Type D Personality for In-stent Restenosis in Coronary Artery Disease Patients Treated With Drug-Eluting Stent. Psychosomatic Medicine 80(1): 95, 2018

Independent predictors of in-stent restenosis after drug-eluting stent implantation for ostial right coronary artery lesions. International Journal of Cardiology 240: 108-113, 2017